



# Arteryal Sertlik ve Nabız Dalga Hızı

Dr. Barış Afşar  
Konya Numune Hastanesi

- **Kompliyans:** Birim basınç değişimine karşın hacimde meydana gelen değişim (cm/mmHg veya  $\text{cm}^2/\text{mmHg}$ )
- **Distensibility:** Esneyebilme. Kompliyans ile aynı manada kullanılıyor
- **Katılık (Sertlik):** Elastik bir maddenin kendisine uygulanan saptırma gücüne karşı olan direnci. Fizyolojik olarak kompliyansın tersi




Elastik




Katı

## Compliant arteries

**Systole** Arterial blood flows through the capillaries throughout systole.



**Diastole** Arterial blood continues to flow through the capillaries throughout diastole.



Normal çalışan kalp sistolde kanı pompalar. Bu sırada aort esnek olduğu için genişler ve enerjiyi depolar. Depolanan bu enerji diyastol sırasında kanın perifere gitmesi için kullanılır ve böylece kan akımı sürekli olur.

- Sistolik Ejeksiyon ile birlikte 2 olay meydana gelir:


Kan ileri doğru atılır (20cm/sn)


Basınç dalgası oluşur (5m/sn)

# Arteryal Sertlik ve Nabız Dalga Hızı


- Oluşan basınç dalgası arter yal ağacın dallanma noktalarında yansımalara uğrar.
- Basınç dalgasındaki bu yansımalarda da arteryal sertlikten etkilenir

# Yansıyan dalga ilk dalganın üstüne biner





# Sistolik basınç ve nabız basıncı artar




# Arteryal Sertlik Artarsa

Yansıyan basınç dalgası daha hızlı hareket ederek daha erken döner. Bunun sonucunda:


- Santral sistolik kan basıncı artarken diastolik basınç düşer ve santral nabız basıncı artar.
- Sol ventrikül kütlesi ve yükü artar. Böylece kalbin iş yükü artar.
- Diyastol sırasında koroner perfüzyon düşer.

# Dalga Yansımaları




Elastik

Sert



## Arterial stiffness in dialysis patients: where are we now?

Mehmet Kanbay · Baris Afsar ·  
Paul Gusbeth-Tatomir · Adrian Covic



# Nabız Dalga Hızını Etkileyen Faktörler

## Arterin Kendine Ait Özellikleri ve Yapısal Değişiklikler

- Arterin yapısı, elastin/kollojen oranı ve elastikiyeti.
  - Elastin oranı arttıkça esneklik artar ve nabız dalga hızı düşer, kollojen oranı arttıkça esneklik azalır nabız dalga hızı yükselir.
  - Glikozaminoglikanların depolanması ve glikasyon son ürünlerinin damar duvarında artışı, damar yapısını bozarak nabız dalga hızını artırır.
- Bramwell and Hill denklemi :  $dV/ dP$  (arter ne kadar elastik ise nabız dalga hızı o kadar yavaş olur)
- Young (Elastisite modülü): Arter ne kadar sert ise değeri artar ve nabız dalga hızı o kadar büyür.

# Nabız Dalga Hızını Etkileyen Faktörler

Arter duvarındaki gerilim, arter çapı ve arter duvarının kalınlığı ile doğru orantılıdır (**Laplace Kanunu**):

Arter ne kadar genişleyebilirse (ne kadar esnek ise) teorik olarak onu eski haline getirmeye yarayan kuvvet (gerilim kuvveti) o kadar yüksek olmalıdır.

# Nabız Dalga Hızını Etkileyen Faktörler

- Yaş
- Kan basıncı

- Kolesterol
- Kan şekeri
- Sigara
- Cinsiyet
- Ateroskleroz ve Arterioskleroz
- Genetik Faktörler
- İnflamasyon

# Expert consensus document on arterial stiffness: methodological issues and clinical applications

Stephane Laurent<sup>1\*</sup>, John Cockcroft<sup>2</sup>, Luc Van Bortel<sup>3</sup>, Pierre Boutouyrie<sup>1</sup>, Cristina Giannattasio<sup>4</sup>, Daniel Hayoz<sup>5</sup>, Bruno Pannier<sup>6</sup>, Charalambos Vlachopoulos<sup>7</sup>, Ian Wilkinson<sup>8</sup>, and Harry Struijker-Boudier<sup>9</sup> on behalf of the European Network for Non-invasive Investigation of Large Arteries

**Table 6** Clinical conditions associated with increased arterial stiffness and/or wave reflections

<i>Ageing</i>	CV risk factors	CV diseases
Other physiological conditions	Obesity	Coronary heart disease
Low birth weight	Smoking	Congestive heart failure
Menopausal status	Hypertension	Fatal stroke
Lack of physical activity	Hypercholesterolaemia	Primarily non-CV diseases
Genetic background	Impaired glucose tolerance	ESRD
Parental history of hypertension	Metabolic syndrome	Moderate chronic kidney disease
Parental history of diabetes	Type 1 diabetes	Rheumatoid arthritis
Parental history of myocardial infarction	Type 2 diabetes	Systemic vasculitis
Genetic polymorphisms	Hyperhomocysteinaemia	Systemic lupus erythematosus
	High CRP level	

# Arteryal Sertlik Nasıl Ölçülür?

Arteryal katılığı ölçerken birçok parametre göz önüne alınmalı:

## A- Ölçüm Yeri:

- **Sistemik:** Aortik NDH (Aortik NDH'ni ölçmek için karotis-femoral NDH transfer fonksiyonu kullanılıyor)
- **Bölgesel:** (Brakial NDH)
- **Lokal:** (Radyal NDH) Lokal yöntemin avantajı direkt olarak ölçüm aletinin ölçüm yapacak damarın üstüne koyulabilmesidir. Dezavantajı santral hemodinamikleri anlamak için transfer fonksiyonuna daha fazla ihtiyaç var.

# Arteryal Sertlik Nasıl Ölçülür?

## B- Ölçüm Yöntemi:

➤ Hız

➤ Basınç

➤ Şekil değişikliği

# Arteryal Sertlik Ölçülür?

## C- Ölçülen Parametre:

- Nabız Dalga Hızı
- Arttırma İndeksi (Augmentaston index)
- Arteryal Kompliyans
- Ambulatuvar Arteryal Sertlik İndeksi
- X ray Kalsifikasyon Skorlaması

## Arterial stiffness in dialysis patients: where are we now?

Mehmet Kanbay · Baris Afsar ·  
Paul Gusbeth-Tatomir · Adrian Covic









Fig. 2 Methods of measuring arterial stiffness



- Bu yöntemler içinde altın standart olan yöntem:

Aortik Nabız Dalga Hızı Ölçümüdür

- Aort Nabız Dalga Hızı Ölçümü:

- Klinikte en sık kullanılan

- Kolay

- Tekrarlanabilir

- Güvenilir

- En iyi prognostik

Metottur

# Stiffness of Capacitive and Conduit Arteries

## Prognostic Significance for End-Stage Renal Disease Patients

Bruno Pannier, Alain P. Guérin, Sylvain J. Marchais, Michel E. Safar, Gérard M. London





Figure 2. Probability of cardiovascular survival of ESRD patients according to the levels of aortic, brachial, and femoral PWVs.

# Stiffness of Capacitive and Conduit Arteries

## Prognostic Significance for End-Stage Renal Disease Patients



Bruno Pannier, Alain P. Guérin, Sylvain J. Marchais, Michel E. Safar, Gérard M. London



**Figure 3.** Receiver operating characteristics curves for pulse pressure, aortic PWV, brachial PWV, and femoral PWV in ESRD patients.

# Impact of Aortic Stiffness Attenuation on Survival of Patients in End-Stage Renal Failure


Alain P. Guerin, MD; Jacques Blacher, MD, PhD; Bruno Pannier, MD; Sylvain J. Marchais, MD; Michel E. Safar, MD; Gérard M. London, MD



# Impact of Aortic Stiffness on Survival in End-Stage Renal Disease


Jacques Blacher, MD; Alain P. Guerin, MD; Bruno Pannier, MD; Sylvain J. Marchais, MD; Michel E. Safar, MD; Gérard M. London, MD

Probability of overall survival



# Aortic Pulse Wave Velocity as a Marker of Cardiovascular Risk in Hypertensive Patients


Jacques Blacher, Roland Asmar, Saliha Djane, Gérard M. London, Michel E. Safar



# Nabız Dalga Hızı Ölçümü

- Aplanasyon Tonometrisi (Sphygmo Cor, Comlior)
- Pletismografi
- Infrared Sensörler (Pulsemetrik)
- Osilometrik Yöntemler (Arteriograph, Mobil-o-Graph)
- Doppler USG, MR (genişleme, şekil değişikliğini ölçer)

# NABIZ DALGA HIZI




$$\text{PWV} = \text{Distance (D)} \quad / \quad \text{Time delay } (\Delta T) \text{ m/sec}$$

Usually measured over 10 heart beats.



## NABIZ DALGA HIZI ANALİZİ

- Applanation tonometry
- Infra-red sensor – digit volume pulse




# Aplanasyon Tonometrisi

- Perifer arterdeki basınç dalgalarının transfer fonksiyonu kullanılarak santral basınç ve santral basınç dalgaları hakkında bilgi sağlanmasıdır.
- Periferik arterdeki basınç dalgaları bu arterlerin üstüne konulan sensörler sayesinde algılanır.
- Bu algılanan basınç dalgaları otomatik olarak (software) ölçülmesi istenen parametreleri (NDH, AiX) ölçer.

# Transfer Fonksiyonu

- Arteryal ağaç boyunca damarlar histolojik, hücresel ve moleküler olarak değişiklik gösterir. Bu durum nabız dalga hızlarınının değişik arter bölümlerinde farklı olmasına neden olur.
- Örneğin NDH çıkan aortada 4–5m/s, abdominal aortada 5–6m/s ve iliak ve femoral arterlerde 8–9m/s civarındadır.
- Bu nedenle perifer damarlardan ölçülen NDH santral NDH'nı öngörebilmesi için bu fizyolojik faktörler göz önüne alınmalıdır.
- Transfer fonksiyonu bu fizyolojik prensibin software tarafından kabaca hesaplanması yoluyla sonuçların düzenlenmesi işlemidir.

# PulseMetric



## CARDIAC PARAMETERS

[Normal Range(Male)\*]

<u>LV Ejection Time (sec)</u>	0.373	[0.207 - 0.388]
<u>LV dP/dt Max (mmHg/s)</u>	1,200	[847 - 1506]
<u>LV Contractility (1/s)</u>	15.95	[12.39 - 19.08]
<u>Cardiac Output (L/min)</u>	4.41	[3.59 - 7.9]
<u>Cardiac Index (L/min/m<sup>2</sup>)</u>	2.47	[1.95 - 3.74]
<u>Stroke Volume (mL)</u>	74.2	[57.7 - 100.7]
<u>Stroke Vol Index (mL/m<sup>2</sup>)</u>	41.6	[31.8 - 48]

## SYSTEMIC VASCULAR PARAMETERS

<u>SV Compliance (mL/mmHg)</u>	1.43	[1.02 - 2]
<u>SV Resistance (dynes/sec/cm<sup>5</sup>)</u>	1598	[871 - 1902]

## BRACHIAL ARTERY PARAMETERS

<u>BA Compliance (mL/mmHg)</u>	0.069	[0.056 - 0.132]
<u>BA Distensibility (%/mmHg)</u>	5.44	[4.38 - 9.28]



Brachial Artery Distensibility, SVR, CO, LV dP/dt

Uses Oscillometric BP cuff

# Sphygmo Cor aleti




# Sphygmocor



**Pulse Wave Velocity & Augmentation Index  
 Uses Arterial tonometer (radial)**

Pulse Contour Analysis for the rapid assessment of arterial stiffness and endothelial function

## Micro Medical



Also Available with PWV option

PulseTrace measures Arterial Stiffness (SI), which has been shown to be an independent predictor of cardiovascular risk that can be used to:

- Assess cardiovascular health, non-invasively
- Identify patients at risk of heart attack and stroke
- Monitor the progress of vascular disease
- Monitor effect of specific drugs

PulseTrace measures Vascular Tone (RI) providing:

- A simple and non-invasive test of endothelial function, an early marker of developing arterial disease.

## Arterial Stiffness & Pulse Contour Analysis


The new Micro Medical PulseTrace provides the clinical information that can aid early detection and treatment of arterial disease. PulseTrace is a powerful non-invasive device that measures two vascular disease parameters: large artery wall stiffness (SI) and vascular tone (RI).

PulseTrace uses pressure wave transmission and reflection theory to evaluate the speed with which the pressure pulse travels through the large arteries, and to estimate vascular tone (determined by the diameter of the small to medium arteries). This theory explains why the pressure pulse waveform changes as it travels through the arterial system<sup>1</sup>.

The speed with which the pressure pulse travels up and down through the arteries is directly related to their stiffness<sup>2</sup> (blood pressure, vessel diameter and blood density are other factors). Measuring the time it takes for the pressure waves to travel through the arterial system provides a simple but accurate way of measuring arterial stiffness<sup>3</sup>.

PulseTrace uses the fact that the pressure waveform in the radial artery is related to the volume waveform in the finger<sup>4</sup>. It is this very important observation that makes the Micro Medical PulseTrace such a powerful non-invasive tool for the assessment of vascular disease.

## Micro Medical



### Wave Transmission & Reflection Theory

The first part of the volume waveform in the finger is the result of pulse transmission along a direct path from the aortic root to the finger. The second part is formed by the pulse transmitted from the aortic root to the lower body where it is reflected back along the aorta and subclavian artery to the finger.

The time delay between the first and second peak is determined by the transit time of the pressure pulse from the root of the subclavian artery to the apparent point of reflection and back to the subclavian artery. Assuming this distance is proportional to the subject's height, the transit time of the pressure pulse in the aorta and large arteries can be used to calculate a stiffness index (see diagram above).

The height of the second peak relates to the amount of pressure wave reflection. This in turn relates mainly to the tone of small arteries. When the second peak is absent then the point of inflection in the down-slope of the waveform is used.

## The Digital Volume Pulse (DVP)

The DVP waveform is directly related to pressure waveform in the radial artery<sup>4</sup> and provides an accurate and noninvasive method to obtain information on the pressure pulse waveform. The Micro Medical PulseTrace uses a high fidelity photoplethysmograph transducer with signal conditioning circuit to obtain an extremely accurate and noise free signal of the DVP waveform. This technique follows the changes in the amount of infra red light passing through the finger, which is inversely proportional to the number of red blood cells (volume of blood) in the finger at any given moment. To maximise the flow of blood, a special temperature controlled heated probe has been developed to optimise signals. This overcomes problems with photoplethysmography in subjects with poorly perfused fingers.




PulseTrace Cat. No. PT2000


### Features

- Minimum user training or special skills needed to obtain clinically valid results
- Well tolerated by the subject
- Fast sequential measurements
- Self contained and portable
- Temperature controlled heating pad (in both the top and bottom of the sensor)
- High resolution printer and colour display
- Complete with all accessories in a sturdy case
- User defined test protocols
- Ectopic beats and artefact rejection
- PC software for uploading and managing results
- Future Proof - can be upgraded via software downloads


## Micro Medical




The **Stiffness Index SI** is an estimate of pulse wave velocity in large arteries and is obtained from the subjects height divided by the time between the first and second peak of the DVP. It is a measure of large artery stiffness.



The **Reflection Index RI** is the height of the second peak of the DVP expressed as a percentage of the waveform peak and is a measure of the tone of the small/medium arteries.



After less than 2 seconds the PulseTrace displays the average waveform based on the number of pulses selected by the user together with the computed SI and RI.



The PulseTrace utilizes software, PC Upload, included with all PulseTrace systems is an Access database that allows you to upload and store your results and waveforms on your PC.

### Specifications

#### Measurements

Averages the digital volume pulse waveforms over a user-defined period (1-60 seconds). Rejects waveforms with low amplitude, artefact or noise and rejects ectopic waveforms. Waveform is visible in real time during sampling period. Calculation time < 2 seconds for a typical recording of 10sec. The points used in the calculations are marked as follows: first peak, systolic inflection point if present and second peak or inflection point. Manual selection of the second peak or inflection point is available.

#### Calculates and displays:

- Total number of waveforms identified
- Total number of waveforms used and their standard deviation
- Time from systolic inflection point (if present) or first peak to second peak or inflection point (PPT)
- Stiffness Index (SI) defined as the subjects height divided by PPT (only displayed if subjects height has been entered)
- Reflection Index (RI) defined as the height of the second peak or inflection point divided by the height of the waveform peak
- Heart Rate

#### Test/Examination

Up to 12 complete tests per examination session

#### Storage

200 examinations including the waveform can be stored

#### Transducer

Precision photoplethysmographic finger probe with temperature controlled heating pad fitted internally to both the top and bottom of the sensor

#### Printer

320 dot per line internal thermal printer

#### Display

1/4 VGA Colour LCD

#### Power Supply

Input 100-250V 50-60Hz. DC output 12V 500mA

#### Dimensions

327 x 140 x 45mm (when display closed). Transducer 20 x 20 x 60mm

#### Weight

Unit weight: 1.1 kg. Packed weight with carry case and accessories 2.6kg

#### Standards

Type B device, CE approved (Directive 90/42/EEC)

#### Environment

Complies with directive EN60601-1-2 electromagnetic compatibility

### Bibliography

- 1 Nichol WW, O'Rourke MF, McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. London: Artek, 1996.
- 2 Bramwell JC, Hillier AG. Velocity of transmission of the pulse wave and elasticity of arteries. *Lancet* 1922; 1: 681-682.
- 3 Millross SC, Kelly RR, Ritter JM and Chouksey PL. Determination of age-related increases in large artery stiffness by digital pulse contour analysis. *Clinical Science* 2002; 102: 371-377.
- 4 Millross SC, Gudgeon FC, Kelly RR, Prasad K, Cockcroft JR, Ritter JM, Chouksey PL. Non-invasive assessment of the digital volume pulse: comparison with the peripheral pressure pulse. *Hypertension* 2000; 35:952-955.

### Micro Medical Limited

PO BOX 6, Rochester,

Kent, ME1 2AZ, UK

Telephone 01634 360044

Fax 01634 360055

International +44 1634 360044

Email [pulsetrace@micromedical.co.uk](mailto:pulsetrace@micromedical.co.uk)

[www.micromedical.co.uk](http://www.micromedical.co.uk)

Micro Medical (Deutschland) GmbH  
Kloster Str. 67c, 25227 Herzingen, Germany  
Tel +49 (0) 435 730 920  
Fax +49 (0) 435 730 917  
Email: [hof@micromedical.co.uk](mailto:hof@micromedical.co.uk)  
[www.micromedical.co.uk](http://www.micromedical.co.uk)



The PulseTrace is manufactured by Micro Medical Ltd and is covered in Catalogue No. PT2000

Micro Medical is a private company and is not responsible for any product or company name changes.  
The appearance of trademarks on any page is not intended as an endorsement.

# PULSE WAVE VELOCITY

The Complior® device




## Expert consensus document on arterial stiffness: methodological issues and clinical applications

Stephane Laurent<sup>1\*</sup>, John Cockcroft<sup>2</sup>, Luc Van Bortel<sup>3</sup>, Pierre Boutouyrie<sup>1</sup>, Cristina Giannattasio<sup>4</sup>, Daniel Hayoz<sup>5</sup>, Bruno Pannier<sup>6</sup>, Charalambos Vlachopoulos<sup>7</sup>, Ian Wilkinson<sup>8</sup>, and Harry Struijker-Boudier<sup>9</sup> on behalf of the European Network for Non-invasive Investigation of Large Arteries

Measurement site	First author (year, country)	Events	Follow-up (years)	Type of patient (number)
Aortic PWV	Blacher (1999, Fr)	CV mortality	6.0	ESRD (241)
	Laurent (2001, Fr)	CV mortality	9.3	Hypertension (1980)
	Meaume (2001, Fr)	CV mortality	2.5	Elderly (>70) (141)
	Shoji (2001, Jp)	CV mortality	5.2	ESRD (265)
	Boutouyrie (2002, Fr)	CHD events	5.7	Hypertension (1045)
	Cruickshank (2002, GB)	All cause mortality	10.7	IGT (571)
	Laurent (2003, Fr)	Fatal strokes	7.9	Hypertension (1715)
	Sutton-Tyrrell (2005, USA)	CV mortality and events	4.6	Elderly (2488)
	Shokawa (2005, Jp)	CV mortality	10	General population (492)
	Willum-Hansen (2006, Dk)	CV mortality	9.4	General population (1678)
	Mattace-Raso (2006, Neth.)	CV mt, CHD	4.1	Elderly (2835)
Ascending aorta (invasive)	Stefanadis (2000, Gr)	Recurrent acute CHD	3	Acute CHD (54)
Carotid distensibility	Blacher (1998, Fr)	All cause mortality	2.1	ESRD (79)
	Barenbrock (2001, Ge)	CV events	7.9	ESRD (68)

# Pulse Wave Velocity Is an Independent Predictor of the Longitudinal Increase in Systolic Blood Pressure and of Incident Hypertension in the Baltimore Longitudinal Study of Aging

Samer S. Najjar, MD<sup>\*</sup>, Angelo Scuteri, MDPH<sup>\*,†</sup>, Veena Shetty, MPH<sup>\*</sup>, Jeanette G. Wright, BA<sup>‡</sup>, Denis C. Muller, MS<sup>‡</sup>, Jerome L. Fleg, MDFACC<sup>§</sup>, Harold P. Spurgeon, PhD<sup>\*</sup>, Luigi Ferrucci, MDPH<sup>‡</sup>, and Edward G. Lakatta, MD<sup>\*</sup>




Subjects at risk

●	72	51	31	21	11	8	4
○	72	59	37	28	13	6	1

# Aortic Pulse Wave Velocity Is Associated With Measures of Subclinical Target Organ Damage

Thais Coutinho, MD,\*† Stephen T. Turner, MD,\*‡ Iftikhar J. Kullo, MD\*†  
Rochester, Minnesota




**Figure 1. Correlations of aPWV With Coronary, Lower Extremity, Cerebral, and Renal Arteriosclerosis**

Scatterplot depicting the unadjusted correlations of aortic pulse wave velocity (aPWV) with log (CAC + 1), ABI, log (WMH), and log (UACR + 1). ABI = ankle-brachial index; CAC = coronary artery calcification; UACR = urine albumin/creatinine ratio; WMH = brain white matter hyperintensity volume.


# Gender-specific brachial artery blood pressure-independent relationship between pulse wave velocity and left ventricular mass index in a group of African ancestry

Elena Libhaber<sup>a,b</sup>, Angela J. Woodiwiss<sup>a</sup>, Carlos Libhaber<sup>b</sup>, Muzi Maseko<sup>a</sup>, Olebogeng H.I. Majane<sup>a</sup>, Siyanda Makaula<sup>a</sup>, Patrick Dessein<sup>a</sup>, Mohammed R. Essop<sup>b</sup>, Pinhas Sareli<sup>a</sup> and Gavin R. Norton<sup>a</sup>



# Relationship between wave reflection and renal damage in hypertensive patients: a retrospective analysis


Francesco Stea<sup>a,b</sup>, Melania Sgrò<sup>b</sup>, Francesco Faita<sup>a</sup>, Rosa M. Bruno<sup>a,b</sup>, Giulia Cartoni<sup>b</sup>, Sabina Armenia<sup>b</sup>, Stefano Taddei<sup>b</sup>, and Lorenzo Ghiadoni<sup>b</sup>



VASCULAR BIOLOGY – HEMODYNAMICS – HYPERTENSION


# Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension

**JEAN-JACQUES MOURAD, BRUNO PANNIER, JACQUES BLACHER, ANNIE RUDNICH, ATHANASE BENETOS, GÉRARD M. LONDON, and MICHEL E. SAFAR**




# Increased Aortic Pulse Wave Velocity Is Associated With Silent Cerebral Small-Vessel Disease in Hypertensive Patients

Léon H.G. Henskens, Abraham A. Kroon, Robert J. van Oostenbrugge, Ed H.B.M. Gronenschild, Monique M.J.J. Fuss-Lejeune, Paul A.M. Hofman, Jan Lodder, Peter W. de Leeuw



**Figure 1.** Plot illustrating the relationship between aortic PWV and WMHV for the total study population ( $n=167$ ). The data points illustrate the predicted WMHV vs the aortic PWV, adjusted for age, sex, and BV. The  $P$  value indicates the significance level for the corresponding linear regression analysis (using log-transformed WMHV). Abbreviations as in Tables.



**Figure 2.** Plot illustrating the relationship between aortic PWV and WMHV for participants younger ( $n=83$ ) and for participants older ( $n=84$ ) than the median age of 52.7 years. The data points illustrate the predicted WMHV vs the aortic PWV, adjusted for age, sex, and BV, and for younger and older participants separately.  $P$  values indicate the significance levels for the corresponding linear regression analyses (using log-transformed WMHV). Abbreviations as in Tables.

# Tedavi

- Arteryal Sertlikte Kullanılan Tedaviler
  - ADEi, ARBs
  - Nitratlar
  - Diuretikler
  - Statinler
  - Aspirin
  - Beta Blokerler
  - Kalsiyum Kanal Blokerleri

- Umut Vadeden Tedaviler:
  - Endopeptidaz inhibitörleri (Omeprazole)
  - Fosfodiesteraz inhibitörleri (Sildenafil )
  - Glikolizasyon son ürün çapraz bağlarını koparan ilaçlar.

# Sonuç

- Santral hemodinamik parametreler, mortalite ve kardiyovasküler prognozu etkiler
- Damar katılığı arttıkça hemodinamik parametreler değişir, sistolik kan basıncı, nabız basıncı ve nabız dalga hızı artar.
- Bu sistol sırasında kalbin iş yükünü artırırken diyastol sırasında kalbin beslenmesini bozar

# Sonuç

- NDH birçok yöntemle, birçok alet kullanarak ve birçok yerden ölçülebilir. Ama altın standart yöntem Aortik NDH'ni ölçmektir.
- Artmış NDH birçok istenmeyen klinik durumla birlikte dir.
- NDH Kan basıncından bağımsız olarak azaltılmasının morbidite ve mortaliteyi azaltıp azaltmayacağını gösteren çalışmalara ihtiyaç vardır.

Teşekkürler...